Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review

Maria Lopez-Santillan; Elixabet Lopez-Lopez; Paula Alvarez-Gonzalez; Garazi Martinez; Javier Arzuaga-Mendez; Irune Ruiz-Diaz; Isabel Guerra-Merino; Angela Gutierrez-Camino; Idoia Martin-Guerrero

doi:10.1016/j.critrevonc.2021.103430

Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review

Crit Rev Oncol Hematol. 2021 Sep:165:103430. doi: 10.1016/j.critrevonc.2021.103430. Epub 2021 Jul 30.

Authors

Maria Lopez-Santillan¹, Elixabet Lopez-Lopez², Paula Alvarez-Gonzalez³, Garazi Martinez³, Javier Arzuaga-Mendez⁴, Irune Ruiz-Diaz⁵, Isabel Guerra-Merino⁶, Angela Gutierrez-Camino⁷, Idoia Martin-Guerrero⁸

Affiliations

¹ Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n 48940, Leioa, Spain; Medical Oncology Service, Basurto University Hospital, Avenida De Montevideo, 18, 48013, Bilbao, Spain.
² Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n 48940, Leioa, Spain; Pediatric Oncology Group, Biocruces Bizkaia Health Research Institute, Plaza Cruces s/n, 48903, Barakaldo, Spain.
³ Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n 48940, Leioa, Spain.
⁴ Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n 48940, Leioa, Spain; Hematologic Neoplasm Group, Biocruces Bizkaia Health Research Institute, Plaza Cruces s/n, Barakaldo, Spain.
⁵ Pathology Department, Donostia University Hospital, Paseo Doctor Begiristain, 109, 20014, San Sebastián, Spain.
⁶ Pathology Department, Araba University Hospital, Calle Jose Atxotegi s/n, 01009, Vitoria-Gasteiz, Spain.
⁷ Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n 48940, Leioa, Spain; Pediatric Oncology Group, Biocruces Bizkaia Health Research Institute, Plaza Cruces s/n, 48903, Barakaldo, Spain; Division of Hematology-Oncology, CHU Sainte-Justine Research Center, 3175 Chemin de la Côte-Sainte-Catherine, H3T 1C5, Montreal, Canada.
⁸ Pediatric Oncology Group, Biocruces Bizkaia Health Research Institute, Plaza Cruces s/n, 48903, Barakaldo, Spain; Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n 48940, Leioa, Spain. Electronic address: idoia.marting@ehu.eus.

PMID: 34339834
DOI: 10.1016/j.critrevonc.2021.103430

Abstract

Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), is a highly heterogeneous and aggressive disease. Regardless of this heterogeneity, all patients receive the same first-line therapy, which fails in 30-40 % of patients, who are either refractory or relapse after remission. With the aim of stratifying patients to improve treatment outcome, different clinical and genetic biomarkers have been studied. The present systematic review aimed to identify somatic mutations that could serve as prognosis biomarkers or as therapeutic target mutations in DLBCL. Regarding their role as prognostic markers, mutations in CD58 and TP53 seem the most promising predictors of poor outcome although the combination of different alterations and other prognostic factors could be a more powerful strategy. On the other hand, different approaches regarding targeted therapy have been proposed. Therefore, mutational analysis could help guide treatment choice in DLBCL yet further studies and clinical trials are needed.

Keywords: Diffuse large B-cell lymphoma; Outcome; Somatic mutation; Therapeutic target.

Publication types

Review
Systematic Review

MeSH terms

DNA Mutational Analysis
Humans
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / genetics
Mutation
Neoplasm Recurrence, Local*
Prognosis